Cognition Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Cognition Therapeutics (NASDAQ: CGTX), a clinical-stage company focused on neurodegenerative disorder treatments, has successfully regained compliance with Nasdaq's minimum bid price requirement. The company met Nasdaq's Rule 5550(a)(2) by maintaining a closing bid price of $1.00 or higher for at least 10 consecutive business days, achieving this milestone on August 25, 2025.
Following this achievement, Nasdaq has officially closed the bid price deficiency matter, confirming Cognition's continued listing on the exchange.
Cognition Therapeutics (NASDAQ: CGTX), società in fase clinica che sviluppa terapie per i disturbi neurodegenerativi, ha ripristinato con successo la conformità al requisito minimo del prezzo di mercato imposto da Nasdaq. La società ha rispettato la Regola 5550(a)(2) di Nasdaq mantenendo un prezzo di chiusura di $1,00 o superiore per almeno 10 giorni lavorativi consecutivi, raggiungendo questo traguardo il 25 agosto 2025.
Di conseguenza, Nasdaq ha formalmente chiuso la questione relativa alla non conformità sul prezzo di quotazione, confermando la permanenza di Cognition nella borsa.
Cognition Therapeutics (NASDAQ: CGTX), una compañía en fase clínica dedicada a tratamientos para trastornos neurodegenerativos, ha recuperado con éxito el cumplimiento del requisito mínimo de precio de cotización de Nasdaq. La empresa cumplió la Regla 5550(a)(2) de Nasdaq al mantener un precio de cierre de $1.00 o más durante al menos 10 días hábiles consecutivos, alcanzando este hito el 25 de agosto de 2025.
Tras este logro, Nasdaq ha cerrado oficialmente el asunto relativo a la deficiencia del precio de cotización, confirmando la continuidad de la cotización de Cognition en la bolsa.
Cognition Therapeutics (NASDAQ: CGTX)는 신경퇴행성 질환 치료제 개발에 주력하는 임상 단계 기업으로, 나스닥의 최소 입찰가 요건을 성공적으로 회복했습니다. 회사는 나스닥 규정 5550(a)(2)를 충족하여 연속 영업일 기준 최소 10일 동안 종가가 $1.00 이상을 유지했으며, 이 기준을 2025년 8월 25일에 달성했습니다.
이에 따라 나스닥은 입찰가 관련 결함 사안을 공식적으로 종결했으며, Cognition의 상장 유지가 확인되었습니다.
Cognition Therapeutics (NASDAQ: CGTX), société en phase clinique spécialisée dans les traitements des troubles neurodégénératifs, a rétabli avec succès sa conformité à l'exigence minimale de prix de Nasdaq. La société a respecté la Règle 5550(a)(2) de Nasdaq en maintenant un cours de clôture de 1,00 $ ou plus pendant au moins 10 jours ouvrables consécutifs, atteignant cet objectif le 25 août 2025.
Suite à cette réalisation, Nasdaq a officiellement clos le dossier relatif à la défaillance du prix d'offre, confirmant le maintien de la cotation de Cognition sur la bourse.
Cognition Therapeutics (NASDAQ: CGTX), ein klinisch tätiges Unternehmen, das sich auf Behandlungen neurodegenerativer Erkrankungen spezialisiert hat, hat die Einhaltung der Mindestnotierungsvoraussetzung der Nasdaq erfolgreich wiederhergestellt. Das Unternehmen erfüllte die Nasdaq-Regel 5550(a)(2), indem es einen Schlusskurs von $1,00 oder höher für mindestens 10 aufeinanderfolgende Handelstage beibehielt und diesen Meilenstein am 25. August 2025 erreichte.
Infolge dessen hat die Nasdaq die Angelegenheit der Kursdefizienz offiziell geschlossen und die Fortführung der Notierung von Cognition an der Börse bestätigt.
- Successfully regained Nasdaq compliance, removing delisting risk
- Maintained share price above $1.00 for required period
- Continues to maintain Nasdaq listing status
- Previous trading below $1.00 minimum bid price requirement indicates recent stock price weakness
PURCHASE, N.Y., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, was notified by The Nasdaq Listing Qualifications Staff (“Nasdaq”) that the Company has regained compliance with the exchange’s continued listing standard for minimum share price under Rule 5550(a)(2) (the “Bid Price Rule”).
To regain compliance with the Bid Price Rule, the Company's shares of common stock were required to maintain a minimum closing bid price of
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., is a clinical-stage biopharmaceutical company discovering and developing innovative, small molecule therapeutics targeting age-related degenerative disorders of the central nervous system. We recently completed Phase 2 studies of our lead candidate, zervimesine (CT1812) in dementia with Lewy bodies (DLB), mild-to-moderate Alzheimer’s disease and geographic atrophy secondary to dry AMD. The Phase 2 START study (NCT05531656) in early Alzheimer’s disease is ongoing with
| Contact Information: Cognition Therapeutics, Inc. info@cogrx.com | Mike Moyer (investors) LifeSci Advisors mmoyer@lifesciadvisors.com |
This press release was published by a CLEAR® Verified individual.
FAQ
Has Cognition Therapeutics (CGTX) regained Nasdaq compliance in 2025?
What is Nasdaq's minimum bid price requirement that CGTX had to meet?
What happens now that CGTX has regained Nasdaq compliance?
What type of company is Cognition Therapeutics (CGTX)?
